Every Cure

Overview

Every Cure is presented as a nonprofit founded to discover and validate new disease uses for existing medicines across the full drug-disease landscape.

Current Profile

The organization addresses a search and incentive gap. Biomedical findings are dispersed across papers, laboratories, patient communities, diseases, and specialties, while generic drugs and rare diseases may attract too little commercial investment for systematic indication expansion. Every Cure’s proposed response is to map biomedical knowledge and use AI or machine learning to rank candidate drug-disease relationships.

Ranking is only the front end. The episode describes a pipeline that can include literature and expert review, laboratory studies, observational evidence, clinical trials, and cautious support for physician-patient decisions. Programs named in the source range from lidocaine around breast-cancer surgery to DFMO for Bachmann-Bupp syndrome; individual rescue cases are also discussed, but they are not equivalent to controlled evidence.

Key Characteristics

• Operates as a nonprofit rather than a one-drug commercial development company.
• Searches across approved drugs and diseases for overlooked treatment matches.
• Uses biomedical knowledge mapping and computational ranking to prioritize scarce attention.
• Escalates promising hypotheses through laboratory, observational, clinical, and expert validation.
• Works across common, rare, and ultra-rare conditions.
• Accepts ideas and expertise from patients, clinicians, and researchers while retaining an evidence gate.

Evidence

• Mission and search model - Using Existing Drugs in New Ways to Treat & Cure Diseases of Brain & Body | Dr. David Fajgenbaum describes an all-drug, all-disease ranking ambition motivated by fragmented knowledge and weak generic-drug incentives.
• Validation pipeline - Using Existing Drugs in New Ways to Treat & Cure Diseases of Brain & Body | Dr. David Fajgenbaum names laboratory studies, trials, observational data, expert review, and clinician-patient judgment as safeguards.
• Program range - Using Existing Drugs in New Ways to Treat & Cure Diseases of Brain & Body | Dr. David Fajgenbaum discusses breast cancer, Castleman disease, angiosarcoma, DADA2, POEMS syndrome, and Bachmann-Bupp syndrome examples at differing evidence levels.

Qualifications

The current evidence is Every Cure co-founder David Fajgenbaum’s podcast account, not an independent audit of the organization, model, funding, portfolio, trials, outcomes, or cost effectiveness. Model rank does not establish mechanism, dose, formulation, safety, efficacy, or clinical applicability. The episode says funding is split roughly between ARPA-H and individuals, but that time-sensitive claim requires current documentary verification.

What Changed

• Established the nonprofit’s drug-repurposing mission, computational prioritization role, and validation pipeline.
• Separated candidate ranking and individual rescue cases from demonstrated treatment efficacy.

Relationships

• David Fajgenbaum - co-founder and public explainer in the current evidence.
• Drug Repurposing - core operating domain.
• AI For Science - broader computational evidence-connection context.
• AI Clinical Validation In Drug Discovery - boundary requiring human evidence after computational prioritization.
• Patient-Led Rare-Disease Infrastructure / 患者主导的罕见病基础设施 - source of needs, observations, networks, and expert connections.
• Food and Drug Administration - regulator relevant to indication-specific approval and evidence pathways.
• Medical Risk Management - safety and decision boundary for novel uses of existing drugs.